好的，这是您提供的英文文本的中文翻译：
欧莱雅研发与创新/Episkin作为金牌赞助商在北京举行的2025年国际毒理学大会（ICT 2025）上展示创新。
国际毒理学大会（ICT 2025）是该领域的一项重要盛会，最近在中国北京圆满落幕，吸引了来自全球的3000多名参与者。欧莱雅研发与创新/Episkin很荣幸能担任此次极具影响力的大会的金牌赞助商，大会强调了毒理学领域的关键进展和讨论。
此次大会因其广泛的毒理学范围而获得了显著的国际关注，促进了中国主要政府机构、领先学术机构和行业先驱的积极参与。著名国际研究人员的出席进一步提升了讨论水平，使ICT 2025成为分享前沿研究和促进合作的关键平台。
欧莱雅对科学进步和安全评估的承诺在整个大会期间得到了显著展示。得益于跨职能和跨国家的卓越协作努力，欧莱雅保持了强大的存在感和高知名度。主要亮点包括：
- Episkin专属展位： 我们的互动式Episkin展位为与会者提供了一个核心交流平台，让他们了解我们先进的体外皮肤模型及其在安全性和功效测试中的应用。
- RHE方法实施的海报展示： 我们展示了一份引人注目的海报，详细介绍了我们重建人体表皮（RHE）方法的实施，强调了我们在替代测试策略方面的专业知识。
- 专门的继续教育会议： 欧莱雅主办了一场专门的继续教育会议，深入探讨了关键主题。本次会议不仅涵盖了Episkin模型的最新发展和应用，还深入介绍了我们用于全身毒性评估的创新型下一代风险评估（NGRA）方法，强调了新方法学（NAMS）的全面整合。
此次大会为毒理学领域不断演变的格局提供了宝贵的见解，强调了全球向更道德、更具预测性且与人类更相关的安全评估方向的转变。我们的积极参与使我们能够为这些关键对话做出贡献，并巩固欧莱雅在非动物测试方法开发和应用方面的领导地位。
ENGLISH
L'Oréal R&I/Episkin Showcases Innovation as Gold Sponsor at ICT 2025 in Beijing, China.
The International Congress of Toxicology (ICT 2025), a seminal event in the field, recently concluded in Beijing, China, drawing over 3,000 participants from across the globe. L'Oréal R&I/Episkin was honored to serve as a Gold Sponsor for this highly impactful congress, which highlighted critical advancements and discussions within toxicology.
The congress garnered significant international attention due to its extensive toxicological scope, fostering robust engagement from key Chinese authorities, leading academic institutions, and industry pioneers. The presence of renowned international researchers further elevated the discourse, making ICT 2025 a pivotal platform for sharing cutting-edge research and fostering collaboration.
L'Oréal's commitment to scientific advancement and safety assessment was prominently displayed throughout the congress. Thanks to exceptional collaborative efforts spanning various functions and countries, L'Oréal maintained a strong presence and high visibility. Key highlights included:
Episkin's Dedicated Booth: Our interactive Episkin booth provided a central hub for attendees to learn about our advanced in vitro skin models and their applications in safety and efficacy testing.
Poster Presentation on RHE Method Implementation: We presented a compelling poster detailing the implementation of our Reconstructed Human Epidermis (RHE) method, underscoring our expertise in alternative testing strategies.
Dedicated Continuing Education Session: L'Oréal hosted a specialized continuing education session that delved into crucial topics. This session not only covered the latest developments and applications of Episkin models but also provided an in-depth look at our innovative Next-Generation Risk Assessment (NGRA) approach for systemic toxicity, emphasizing the full integration of New Approach Methodologies (NAMS).
The congress provided invaluable insights into the evolving landscape of toxicology, emphasizing the global shift towards more ethical, predictive, and human-relevant safety assessments. Our active participation allowed us to contribute to these critical conversations and reinforce L'Oréal's leadership in the development and adoption of non-animal testing methods.